The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
The old rules no longer apply. In today’s complex and competitive pharma environment, drug developers who rely on fragmented outsourcing models risk falling behind. Spreading critical functions across multiple vendors may seem flexible—but this can often lead to operational inefficiencies, delayed timelines, and increased risk.
This white paper challenges conventional thinking and presents a smarter, more strategic approach—one embodied by Accelerator™ Drug Development, Thermo Fisher Scientific’s CDMO and CRO solutions. By consolidating development and manufacturing within a connected partnership, biotech and biopharma companies can:
- Align expertise and infrastructure across the full lifecycle
- Reduce friction, risk, and delays to development
- Adapt more quickly to regulatory and market shifts
Explore how redefining value—beyond just cost and speed—can position your program for long-term success.
